Apyx Medical Corp
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
APYX$2.94+0.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Equity for the
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In thousands)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Non-controlling Interest · Total Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Par Value | |||||||
| Balance at December 31, 2022 | 34,598 | $35 | $73,282 | $(35,735) | $211 | $37,793 | |
| Stock based compensation | — | — | 1,367 | — | — | 1,367 | |
| Proceeds from debt allocated to warrants | — | — | 586 | — | — | 586 | |
| Net loss | — | — | — | (3,483) | (49) | (3,532) | |
| Balance at March 31, 2023 | 34,598 | $35 | $75,235 | $(39,218) | $162 | $36,214 | |
| Balance at December 31, 2023 | 34,644 | $35 | $81,114 | $(54,448) | $221 | $26,922 | |
| Stock based compensation | — | — | 1,128 | — | — | 1,128 | |
| Net loss | — | — | — | (7,576) | (14) | (7,590) | |
| Balance at March 31, 2024 | 34,644 | $35 | $82,242 | $(62,024) | $207 | $20,460 | |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(7,590) | $(3,532) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 157 | 203 |
| Provision for inventory obsolescence | 7 | — |
| Loss on disposal of property and equipment | 20 | — |
| Stock based compensation | 1,128 | 1,367 |
| Allowance for credit losses | — | (142) |
| Non-cash lease expense | 31 | — |
| Non-cash interest expense | 221 | 67 |
| Changes in operating assets and liabilities: | ||
| Trade receivables | 1,478 | 837 |
| Prepaid expenses and other assets | 241 | 858 |
| Income tax receivables | — | (207) |
| Inventories | 138 | 879 |
| Accounts payable | (599) | (776) |
| Accrued expenses and other liabilities | (1,573) | (1,435) |
| Net cash used in operating activities | (6,341) | (1,881) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (35) | (110) |
| Net cash used in investing activities | (35) | (110) |
| Cash flows from financing activities | ||
| Proceeds from long-term debt | — | 9,289 |
| Payment of debt issuance costs | — | (1,754) |
| Proceeds from debt allocated to warrants | — | 586 |
| Repayment of finance lease liabilities | (5) | (9) |
| Net cash (used in) provided by financing activities | (5) | 8,112 |
| Effect of exchange rates on cash | 11 | (58) |
| Net change in cash and cash equivalents | (6,370) | 6,063 |
| Cash and cash equivalents, beginning of period | 43,652 | 10,192 |
| Cash and cash equivalents, end of period | $37,282 | $16,255 |
| Cash paid for: | ||
| Interest | $1,175 | $1 |
| Income taxes | 6 | 125 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.